Kintara Therapeutics Inc (NASDAQ: KTRA) has announced that the VAL-083 treatment arm in the Global Coalition for Adaptive Research registrational Phase .
Kintara Therapeutics Provides Positive Site Activation Update on GCAR Phase 2/3 Clinical Trial for Glioblastoma
News provided by
Share this article
Share this article
SAN DIEGO, May 26, 2021 /PRNewswire/ Kintara Therapeutics, Inc. (Nasdaq: KTRA) ( Kintara or the Company ), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that the VAL-083 treatment arm in the Global Coalition for Adaptive Research (GCAR) registrational Phase 2/3 clinical trial for glioblastoma multiforme (GBM) has been activated in 15 U.S. sites as of May 14, 2021.
The trial, titled GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment), is a patient-centered, adaptive platform trial for registration evaluating multiple therapies for patients with newly-diagnosed and recurrent GBM. Since January 2021, GCAR has accelerated the pace of clinical site activation with increased awareness in the medical community of Kintara s arm of
Asian/Pacific American Heritage (AAPI)
Month is celebrated annually during the month of May. It marks the celebration of Asians and Pacific Islanders in the United States. It includes people having origins from the continent of Asia and the Pacific islands of Melanesia and Polynesia. Asian Americans and Pacific Islanders have a rich culture and heritage spanning thousands of years that have shaped the modern history of the US.
AAPI Heritage commemoration was first proposed in 1977 to observe the immigration of the first Japanese to the US (May 7, 1843) and the completion of the transcontinental railroad, constructed mainly by Chinese immigrant workers (May 10, 1869). President Carter made it an annual week-long event in 1978, and eventually, President George H.W. Bush extended the proclamation to include the entire month of May.
Kintara Therapeutics ends fiscal 3Q with cash and cash equivalents of about $15.7M
The capital runway is expected to be sufficient to fund the company s planned operations to the second quarter of calendar year 2022 Kintara achieved the healthy cash stockpile primarily due to the exercise of warrants as well as operational and resource synergies realized through the Adgero Biopharmaceuticals merger in August 2020
Kintara Therapeutics Inc (NASDAQ:KTRA), which is focused on the development of new solid tumor cancer therapies, said it closed its fiscal third quarter with cash and cash equivalents of about $15.7 million.
That capital, the company said, is expected to be sufficient to fund its planned operations to the second quarter of calendar year 2022.
Kintara Presents Updates on Two Phase 2 Clinical Trials at the 2021 American Association for Cancer Research Annual Meeting
News provided by
Share this article
Share this article
SAN DIEGO, April 12, 2021 /PRNewswire/ Kintara Therapeutics, Inc. (Nasdaq: KTRA) ( Kintara or the Company ), a biopharmaceutical company developing novel cancer therapies for patients who are failing, or resistant to, current treatment regimens, today announced interim data results from two Phase 2 clinical trials evaluating VAL-083, the Company s lead compound, for the treatment of glioblastoma multiforme (GBM). The data were presented in two posters at the 2021 American Association for Cancer Research (AACR) Annual Meeting, which is taking place virtually from April 10-15, 2021.